This site is intended for healthcare professionals
Drug news

FDA advisory committee votes against approving Exondys (eteplirsen) for Duchenne muscular dystrophy amenable to exon 51 skipping- Sarepta Therapeutics

Read time: 1 mins
Last updated:28th Apr 2016
Published:28th Apr 2016
Source: Pharmawand
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest